Home > PKC & PKC  & Apoptosis Inducer & > (-)-Epigallocatechin Gallate

(-)-Epigallocatechin Gallate

(-)-表没食子儿茶素没食子酸酯,EGCG,ECGC

(-)-Epigallocatechin Gallate(EGCG)是多酚类黄酮抗氧化剂,能抑制端粒酶和DNA甲基转移酶,还能阻断EGF和HER-2的受体活性。

目录号
EY0656
EY0656
EY0656
纯度
99.14%
99.14%
99.14%
规格
50 mg
100 mg
500 mg
原价
320
500
1500
售价
320
500
1500
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    (-)-Epigallocatechin Gallate (EGCG) is a strong polyphenol catechin antioxidant found in green tea, reported to have broad efficacy against many conditions generated from oxidative damage. Also a DNMT1 inhibitor. Extensive oxidation of low density lipoproteins is correlated to cardiovascular diseases, and EGCG is reported to strongly inhibit Cu(2+)-mediated oxidative modification of LDLs. The antiapoptotic proteins Bcl-2 and Bcl-x(L) are observed to suppress apoptosis and convey survival to heavily damaged and mutated cells in vitro, and EGCG (along with the other catechins) is shown to directly inhibit these proteins, reestablishing the normal apoptotic pathway in the cell. EGCG also inhibits NOS2. Reduces Aβ42-induced cell death in three different cell types. Also inhibits β-secretase (IC50 = 1.6 μM) and glutamate dehydrogenase GDH. Inhibits cell growth and selectively induces apoptosis in A431 and human pancreatic cancer cells.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    Cells[1]


    The SW780 cells were cultured in Dulbecco’smodified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine serum and 1%penicillin–streptomycin at 37°C in 5% CO2 humidified incubator.

    Cellviability assay

    Cells (1×104/well) were seededin 96-well plates and incubated with different concentrations of EGCG for 24and 48 h. Following incubation, 30μl of MTT solution [5 mg/ml inphosphate-buffered saline (PBS)] was added to each well, and the plate was incubatedat 37°C for another 4 h. Then, the medium was discarded and150μl of DMSO wasadded to dissolve the formazan crystals. The absorbance of each sample was readat 540 nm using a microplate reader.


  • 动物实验

    Animal experiments[2]


    Male Wistar rats (six weeks old), with anaverage weight of 160 g, were housed at a constant temperature (23 ± 1 oC)with a12 h light-dark cycle in stainless steel wire-bottomed cages, and fed acommercial rodent chow (CE-2) and tap water ad libitum. The rats were fastedovernight and assigned to treatment groups (4–6 rats per group). (-)-EpigallocatechinGallate (EGCg) dissolved in distilled water or vehicle was administered orallyto rats at a dose of 500 mg/kg. The plasma EGCg concentration peaked at 60–120min after administration, therefore the rats were anesthetized withpentobarbital90 min after administration and exsanguinated from the abdominalaorta with a heparinized syringe to obtain the blood. In a separate experiment,rats were orally administered 100, 250, 500 mg/kg EGCg, or vehicle, and werethen anesthetized and exsanguinated as described above to analyze the ascorbicacid concentrations in plasma, lymphocytes, and adrenal glands.

    Assayof antioxidant activity

    The ORAC assay was carried out. In brief,50μL of sample was mixed with 150μL of 19.6nmol/L fluorescein solutions in a 96-well microplate and incubated at 37oCfor 10 min, and then 50μL of 20mM AAPH solution was added to initiate the reaction. Trolox wasused as a control standard. The fluorescence intensity at 490nm (excitation)/530nm(emission) was measured every 2 min for 2 h at 37oC using amicroplate fluorescence reader. The FRAP assay was performed. In brief, 40μLof sample was mixed with 1.2 mL of working FRAP solution in a test tube. At 4min after sample-reagent mixing, the absorbance at 593nm was measured against areagent blank at 37 oC using a UV-1600 spectrophotometer.


  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Luo KW, Wei C, Lung WY, et al. EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9. J Nutr Biochem. 2017;41:56-64.
    [2] Yokotani K, Umegaki K. Evaluation of plasma antioxidant activity in rats given excess EGCg with reference to endogenous antioxidants concentrations and assay methods. Free Radic Res. 2017;51(2):193-199.
    [3] Shankar et al (2008) EGCG inhibits growth, invasion, angiogenesis and metastastasis of pancreatic cancer. Front.Biosci. 13 440.
    [4] Lee et al (2005) Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol.Pharmacol. 68 1018.
    [5] Ahmad et al (2000) Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Ach.Biochem.Biophys. 376 338.

    分子式
    C22H18O11
    分子量
    458.37
    CAS号
    989-51-5
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    >20 mg/mL
    Water
    >5 mg/mL
    Ethanol
    >20 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00951834 Alzheimer's Disease Drug: Epigallocatechin-Gallate|Drug: Placebo Charite University, Berlin, Germany Phase 2|Phase 3 2009-10-01 2016-01-20
    NCT01357681 Huntington Disease Drug: (2)-epigallocatechin-3-gallate (EGCG)|Drug: Placebo Charite University, Berlin, Germany Phase 2 2011-09-01 2015-06-15
    NCT01744587 NPC Other: Epigallocatechin Gallate (EGCG)|Dietary Supplement: Placebo National Health Research Institutes, Taiwan|Mackay Memorial Hospital|Taichung Veterans General Hospital|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital|China Medical University Hospital|National Taiwan University Hospital Phase 2|Phase 3 2013-04-01 2016-11-08
    NCT00942422 Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition Dietary Supplement: defined green tea catechin extract|Genetic: gene expression analysis|Genetic: protein analysis|Other: laboratory biomarker analysis Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Phase 2 2009-11-01 2015-03-18
    NCT02008721 Multiple System Atrophy Drug: EGCG as putative neuroprotective agent|Drug: Placebo Dr. Johannes Levin|German Center for Neurodegenerative Diseases (DZNE)|Deutsche Parkinson Vereinigung|Deutsche Stiftung Neurologie|ParkinsonFonds Deutschland gGmbH|Ludwig-Maximilians - University of Munich Phase 3 2014-01-01 2016-12-28
    NCT00459407 Adenocarcinoma of the Prostate|Stage I Prostate Cancer|Stage II Prostate Cancer Dietary Supplement: defined green tea catechin extract|Drug: placebo|Other: immunohistochemistry staining method|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Procedure: biopsy|Other: mass spectrometry|Other: high performance liquid chromatography National Cancer Institute (NCI) Phase 1 2007-03-01 2014-10-07
    NCT00303823 Cervical Cancer|Cervical Intraepithelial Neoplasia Grade 1|Human Papilloma Virus Infection Drug: placebo|Dietary Supplement: defined green tea catechin extract|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2005-09-01 2015-04-14
    NCT00799890 Multiple Sclerosis Drug: Sunphenon EGCG|Drug: Placebo Charite University, Berlin, Germany|TAIYO EUROPE Phase 2|Phase 3 2009-05-01 2016-03-21
    NCT01511263 Primary Amyloidosis of Light Chain Type Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG IRCCS Policlinico S. Matteo Phase 2 2012-01-01 2016-02-24
    NCT00134381 Healthy Drug: Green Tea Rutgers, The State University of New Jersey|Rutgers University Phase 2 2003-05-01 2015-02-02
    NCT00573885 Lung Cancer|Tobacco Use Disorder Drug: defined green tea catechin extract|Other: placebo British Columbia Cancer Agency|National Cancer Institute (NCI)|University of Cincinnati Phase 2 2008-01-01 2012-03-07
    NCT00611650 Lung Cancer|Precancerous Condition|Tobacco Use Disorder Drug: defined green tea catechin extract|Other: placebo British Columbia Cancer Agency|National Cancer Institute (NCI)|University of Cincinnati Phase 2 2006-10-01 2012-03-07
    NCT01993966 Urothelial Carcinoma National Taiwan University Hospital 2014-01-01 2013-11-19
    NCT00596011 Prostatic Hyperplasia Drug: Polyphenon E|Drug: Placebo H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) Phase 2 2007-12-01 2016-11-15
    NCT00253643 Precancerous Condition|Prostate Cancer Dietary Supplement: green tea catechin extract|Dietary Supplement: fish oil|Other: placebo|Other: placebo OHSU Knight Cancer Institute|United States Department of Defense|National Cancer Institute (NCI) 2005-07-01 2015-02-17
    NCT00917735 Breast Cancer Drug: Green tea extract supplement|Other: Placebo University of Minnesota - Clinical and Translational Science Institute|National Cancer Institute (NCI) Phase 2 2009-07-01 2016-01-25

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :